Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling
MILANO, Italy, Jan. 28, 2022 /PRNewswire/ -- FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels) setting in motion a crucial trial in the Native Coronary Vessel Treatment domain....
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. MSA is a devastating neurodegenerative...
“Don’t forget leprosy” campaign gathers pace as World Leprosy Day approaches
TOKYO, Jan. 28, 2022 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative is collaborating with 32 organizations from 13 countries to promote the message "Don't forget leprosy" in the run-up to World Leprosy Day on January 30. The international campaign includes awareness-raising events and outreach to governments, and is being publicized via newspapers, television, radio and social media. Based...
Getinge Year End Report 2021: “Healthy order growth, improved EBITA margin and strong cash flow”
GOTHENBURG, Sweden, Jan. 28, 2022 /PRNewswire/ -- "The organic order intake increased 6.4% in the fourth quarter following growth in all business areas and regions", says Mattias Perjos, President & CEO at Getinge. "Excluding currency effects, our order bookings are more than 20% larger compared with one year ago." As expected, Getinge's net sales declined compared with Q4 2020...
ESTA launches “ULTRABloom” Foam Hand Sanitiser, that is alcohol free with natural moisturising floral botanicals
SINGAPORE, Jan. 28, 2022 /PRNewswire/ -- ESTA Technology proudly launches the floral based ESTA ULTRABloom. Made purely from botanical floral sources, with a subtly sweet fragrance, ESTA ULTRABloom is the first of its range under ESTA Technology Pte Ltd. It is alcohol free, thus suitable for sensitive skin and is also kid friendly. Non-alcohol sanitisers are moisturizing and good for use daily....
Ready to Enter the Middle East Market, Vazyme Showcases Its COVID-19 Testing Solutions at Medlab Middle East 2022
DUBAI, UAE, Jan. 28, 2022 /PRNewswire/ -- Leading China-based biotech company Vazyme (688105.SH) participated in the 2022 edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) from January 24th to 27th, a leading laboratory and flagship exhibition and conference that brings together global medical communities to display the best laboratory innovation and technology. At Booth No....
Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis Expected to accelerate growth in biosimilars and novel therapeutics R&D Purchase to be...
HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN) HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies BASEL, Switzerland and SYDNEY, Jan. 28, 2022 /PRNewswire/ -- HaemaLogiX Ltd (HaemaLogiX), the clinical-stage biotechnology company...
Enable Injections Announces $215 Million Financing
New financing provides significant financial flexibility to propel growth efforts, benefitting patients, providers, and pharma partners worldwide. CINCINNATI, Jan. 27, 2022 /PRNewswire/ -- Enable Injections, Inc. ("Enable"), a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce $215 million in Series C financing. Magnetar Capital...
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital. This latest round comes on the heels of a $18 million Series A...
